DR. CHRISTINE ANNA WHITE, M.D.
Osteopathic Medicine in Rancho Santa Fe, CA
License number
California G44355
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
6591 Calle Tierra Blanca, Rancho Santa Fe, CA 92067
Phone
(858) 405-7825
(858) 759-2747 (Fax)
(858) 759-2755 (Fax)
(858) 759-2747 (Fax)
(858) 759-2755 (Fax)
Professional information
Treatment Of B-Cell Associated Diseases Such As Malignancies And Autoimmune Diseases Using A Cold Anti-Cd20 Antibody/Radiolabeled Anti-Cd22 Antibody Combination
US Patent:
2005011, May 26, 2005
Filed:
Nov 10, 2003
Appl. No.:
10/703669
Inventors:
Christine White - Rancho Santa Fe CA, US
International Classification:
A61K051/00, A61K039/395
US Classification:
424001490, 424144100
Abstract:
Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN® and a radiolabeled anti-CD22 antibody, preferably an Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN® and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
Treatment Of Hematologic Malignancies Associated With Circulating Tumor Cells Using Chimeric Anti-Cd20 Antibody
US Patent:
7682612, Mar 23, 2010
Filed:
Nov 9, 1999
Appl. No.:
09/436347
Inventors:
Christine A. White - Rancho Santa Fe CA, US
John G. Curd - Hillsborough CA, US
Susan Desmond-Hellmann - Alamo CA, US
John G. Curd - Hillsborough CA, US
Susan Desmond-Hellmann - Alamo CA, US
Assignee:
Biogen Idec Inc. - Cambridge MA
Genentech, Inc. - South San Francisco CA
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61K 51/00
US Classification:
4241381, 424 149, 4241331, 4241431, 4241441, 4241531, 4241561, 4241741, 530350, 5303871, 5303873, 5303877, 5303881, 5303882, 53038873, 5303888, 53038885, 5303913
Abstract:
Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
Dr. Christine A White, Rancho Santa Fe CA - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
6591 Calle Tierra Blanca, Rancho Santa Fe 92067
(858) 405-7825 (Phone), (858) 759-2747 (Fax)
(858) 405-7825 (Phone), (858) 759-2747 (Fax)
Languages:
English
Education:
Medical School
University Of Chicago/The Pritzker School Of Medicine
Graduated: 1978
University Ca San Diego Med Center
University Of Chicago Hosps
University Of Chicago/The Pritzker School Of Medicine
Graduated: 1978
University Ca San Diego Med Center
University Of Chicago Hosps
Clinical Parameters For Determining Hematologic Toxicity Prior To Radioimmunotheraphy
US Patent:
6451284, Sep 17, 2002
Filed:
Jul 26, 2000
Appl. No.:
09/625856
Inventors:
Christine A. White - Rancho Santa Fe CA
Assignee:
IDEC Pharmaceuticals Corporation - San Diego CA
International Classification:
A61K 4900
US Classification:
424 92, 424 111, 424 149
Abstract:
New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
Clinical Parameters For Determining Hematologic Toxicity Prior To Radioimmunotherapy
US Patent:
2007014, Jun 28, 2007
Filed:
Feb 27, 2007
Appl. No.:
11/679687
Inventors:
Christine White - Rancho Santa Fe CA, US
International Classification:
G01N 33/574
US Classification:
435007230
Abstract:
New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
Treatment Of Aggressive Non-Hodgkins Lymphoma With Anti-Cd20 Antibody
US Patent:
8557244, Oct 15, 2013
Filed:
Jul 28, 2000
Appl. No.:
09/628187
Inventors:
Christine White - Rancho Santa Fe CA, US
Antonio Grillo-Lopez - Rancho Santa Fe CA, US
Antonio Grillo-Lopez - Rancho Santa Fe CA, US
Assignee:
Biogen Idec Inc. - Weston MA
International Classification:
A61K 39/395, A61K 31/661, A61K 31/664, A61K 31/704, A61K 31/56, C07K 14/705
US Classification:
4241441, 4241301, 4241331, 4241381, 4241411, 4241431, 4241521, 4241531, 4241551, 4241561, 424801
Abstract:
This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.
Treatment Of B-Cell Associated Diseases
US Patent:
6846476, Jan 25, 2005
Filed:
Jun 20, 2001
Appl. No.:
09/883962
Inventors:
Christine White - Rancho Santa Fe CA, US
Assignee:
IDEC Pharmaceuticals Corporation - San Diego CA
International Classification:
A61K 5100
US Classification:
424 149, 424 169
Abstract:
Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN® and a radiolabeled anti-CD22 antibody, preferably an Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN® and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
Clinical Parameters For Determining Hematologic Toxicity Prior To Radioimmunotherapy
US Patent:
7195750, Mar 27, 2007
Filed:
Jul 16, 2002
Appl. No.:
10/195426
Inventors:
Christine A. White - Rancho Santa Fe CA, US
Assignee:
Biogen IDEC Inc. - Cambridge MA
International Classification:
A61K 51/00, A61K 36/14
US Classification:
424 149, 424 164, 4241301, 4241411
Abstract:
New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
Treatment Of Chronic Lymphocytic Leukemia Using Anti-Cd20 Antibodies
US Patent:
8206711, Jun 26, 2012
Filed:
Dec 2, 2009
Appl. No.:
12/629472
Inventors:
Christine A. White - Rancho Santa Fe CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
John G. Curd - Hillsborough CA, US
Susan Desmond-Hellmann - Alamo CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
John G. Curd - Hillsborough CA, US
Susan Desmond-Hellmann - Alamo CA, US
Assignee:
Biogen Idec Inc. - Cambridge MA
Genentech, Inc. - South San Francisco CA
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61K 51/00
US Classification:
4241381, 424 149, 4241331, 4241431, 4241441, 4241531, 4241561, 4241741, 530350, 5303871, 5303873, 5303877, 5303881, 5303882, 53038873, 5303888, 53038885, 5303913
Abstract:
Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.